| 
Surprised there is no subject on BCR.
        
            | | An SI Board Since February 2000 | 
 
                    
                        | Posts | SubjectMarks | Bans | Symbol |  
                    
                        | 5 | 0 | 0 | BCR |  
                    
                        | Emcee: 
                            
                                Bosco | Type: 
                            
                            Unmoderated |  |  
 The following is copied from Yahoo! Profile
 
 C. R. Bard, Inc. develops, manufactures and markets health care                                          products. Bard is engaged in the design, manufacture, packaging,                                          distribution and sale of medical, surgical, diagnostic and patient                                          care devices. Bard's largest product group, urological diagnosis                                          and intervention, includes Foley catheters, procedure kits and                                          trays and related urine monitoring and collection systems, ureteral                                          stents and specialty devices for incontinence, endoscopic                                          procedures and stone removal. Vascular diagnosis and                                          intervention products include peripheral angioplasty stents,                                          catheters, guidewires, introducers and accessories and vena cava                                          filters, electrophysiology products including cardiac mapping and                                          electrophysiology laboratory systems, and diagnostic and                                          temporary pacing electrode catheters, fabrics and meshes and                                          implantable blood vessel replacements. Other products include                                          biopsy products, specialty access catheters and ports,                                          gastroenterological products and meshes for hernia repair.
 
 As of 02/16/2000, share price is near the 52 weeks low. Trailing p/e is less than 19, p/b is under 4 and p/s is under 3. Projected peg is under 1. Debt is .44. She is trading at about 4x cash flow [EBITDA/Market Cap.] She is a S&P 5 stars and one of the Power Picks. S&P thinks it can grow by 15% in the next 3 years or so. It also thinks she is a potential takeover target.
 | 
    |  |